SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1384)2/26/2005 9:06:43 AM
From: rkrw  Respond to of 1834
 
I don't think the androgel copromote is any great shakes. Maybe it will help a little bit. Reminds of the sepr medpointe copromote when sepr had the same trouble finding a second product.

icos projects the JV to make $40-70M this year. Modest growth for 06 and continued declining costs and I bet it could throw off $200M+ that year. I think icos is setting up to sell to lly.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News